Compare Unilever plc (UL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs GeneDx Holdings Corp — how do they compare? Unilever plc trades at $62.45 (market cap $136.96B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Unilever plc is far larger — about 53.5× GeneDx Holdings Corp's market cap, and Unilever plc pays a 3.34% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| UL | WGS | |
|---|---|---|
Market Cap | $136.96B | $2.56B |
Sector | Consumer Staples | Technology |
52-Week High | $74.59 | $167.51 |
52-Week Low | $55.05 | $34.51 |
Enterprise Value | $162.94B | $2.60B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $63.54, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings misses contrast with strong profitability, including a net income margin of 18.32% and ROE of 54.57% for 2025. The company reported its strongest quarterly volume growth in over a decade in Q2 2026, raising its full-year outlook, while strategic shifts include focusing on beauty and personal care and a planned $65 billion merger with McCormick.
The outlook is mixed: robust fundamentals and strategic refocusing support long-term growth, particularly in emerging markets, but consistent earnings misses and a high P/E ratio of 21.46 pose valuation concerns. Risks include integration challenges from the McCormick deal and competitive pressures. Analyst consensus is divided, with 24% buy ratings, highlighting cautious optimism amid execution uncertainties.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
